SELLAS Life Sciences Group (SLS) Price & Analysis

Compare

1,155 Followers

SLS Stock Chart & Stats

$1.91

-$0.10(-9.43%)

At close: Jan 08 4:00 PM EST

$1.91

-$0.10(-9.43%)

Day’s Range― - ―

52-Week Range$0.77 - $2.48

Previous CloseN/A

Volume1.43M

Average Volume (3M)4.05M

Market Cap

$259.24M

Enterprise Value$130.70M

Total Cash (Recent Filing)$44.42M

Total Debt (Recent Filing)$599.00K

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Mar 13, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding142,442,250

10 Day Avg. Volume4,587,537

30 Day Avg. Volume4,050,973

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)67.25

Price to Sales (P/S)0.00

P/FCF Ratio-17.98

Enterprise Value/Market Cap0.50

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-4.55

Forecast

1Y Price Target

$7.25

Price Target Upside279.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsTop-line data from the pivotal P3 study of galinpepimut-S (GPS) in AML is expected to be a key event for SLS shares, with a favorable view on the outcome.

Drug DevelopmentSLS009 positive data from the P2 program in relapsed/refractory AML supports its movement into a later-stage study in 1L, which is significant for drug development trends in AML.

Financial ResourcesThe company raised $29.1M via warrant exercises, providing financial runway into 2027 through the upcoming P3 top-line GPS data and initiation of the 1L AML trial.

Bears Say

SELLAS Life Sciences Group News

Unusually active option classes on open December 8th

Unusual total active option classes on open include: Euro ETF (FXE), CME Group (CME), Sellas Life Sciences (SLS),...

4d ago

CAH

CME

Sellas Life Sciences presents Phase 2 study of SLS009

SELLAS Life Sciences (SLS) announced that clinical data from its ongoing Phase 2 study of SLS009, a highly...

4d ago

SLS

Sellas Life Sciences reports Q3 EPS (6c), consensus (8c)

“We remain highly encouraged by the continued, strong execution across our programs and the expanding body of clinical...

30d ago

SLS

Sellas Life Sciences options imply 12.3% move in share price post-earnings

Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 142:1. Implied volatility suggests...

30d ago

SLS

Buy Rating for SELLAS Life Sciences Group: Financial Stability and Promising Clinical Developments Drive Positive Outlook

SELLAS Life Sciences Group, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason...

28d ago

SLS

Sellas Life Sciences Reports Q3 2025 Financial Results

Sellas Life Sciences Group ( ($SLS) ) has released its Q3 earnings. Here is a breakdown of the...

29d ago

SLS

SLS Upcoming Earnings Report: What to Expect?

Sellas Life Sciences Group (SLS) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall...

1M ago

SLS

Promising Clinical Developments and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on SELLAS Life Sciences Group, with a price...

1M ago

SLS

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 46.53%...

1M ago

BTQ

SLS

Unusually active option classes on open October 27th

Unusual total active option classes on open include: Asset Entities Inc (ASST), Enterprise Products (EPD), YPF (YPF), Unusual...

2M ago

SELLAS Life Sciences Enters Warrant Inducement Agreement

SELLAS Life Sciences Group ( ($SLS) ) just unveiled an announcement. On October 24, 2025, SELLAS Life Sciences...

2M ago

SLS

Sellas Life Sciences announces exercise of warrants for $31M in proceeds

SELLAS Life Sciences (SLS) announced the immediate exercise of warrants, previously issued in March and August 2024, to...

2M ago

SLS

Sellas Life Sciences to present in vivo preclinical data on SLS009

SELLAS Life Sciences (SLS) announced that preclinical efficacy of its highly selective CDK9 inhibitor, SLS009, as a monotherapy...

2M ago

SLS

Sellas Life Sciences files to sell 19.69M shares of common stock for holders

16:09 EDT Sellas Life Sciences (SLS) files to sell 19.69M shares of common stock for holders Published first...

2M ago

SLS

SLS FAQ

What was Sellas Life Sciences Group’s price range in the past 12 months?

Sellas Life Sciences Group lowest stock price was $0.77 and its highest was $2.48 in the past 12 months.

What is Sellas Life Sciences Group’s market cap?

Sellas Life Sciences Group’s market cap is $259.24M.

When is Sellas Life Sciences Group’s upcoming earnings report date?

Sellas Life Sciences Group’s upcoming earnings report date is Mar 13, 2026 which is in 91 days.

How were Sellas Life Sciences Group’s earnings last quarter?

Sellas Life Sciences Group released its earnings results on Nov 12, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.077 by $0.017.

Is Sellas Life Sciences Group overvalued?

According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sellas Life Sciences Group pay dividends?

Sellas Life Sciences Group does not currently pay dividends.

What is Sellas Life Sciences Group’s EPS estimate?

Sellas Life Sciences Group’s EPS estimate is -0.07.

How many shares outstanding does Sellas Life Sciences Group have?

Sellas Life Sciences Group has 142,442,250 shares outstanding.

What happened to Sellas Life Sciences Group’s price movement after its last earnings report?

Sellas Life Sciences Group reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.077. Following the earnings report the stock price went down -2.013%.

Which hedge fund is a major shareholder of Sellas Life Sciences Group?

Currently, no hedge funds are holding shares in SLS

SELLAS Life Sciences Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

-84.33%

Trailing 12-Months

Asset Growth

94.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sellas Life Sciences Group

SELLAS Life Sciences Group (SLS) is a biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. The company's core product is galinpepimut-S (GPS), which is designed to stimulate an immune response against specific cancer cells. SELLAS is involved in clinical trials and research collaborations to advance its pipeline and bring innovative cancer treatments to market.

SELLAS Life Sciences Group (SLS) Earnings & Revenues

Historic Earnings Reports

SLS Stock 12 Month Forecast

Average Price Target

$7.25

▲(279.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,2.256923076923077,2.693846153846154,3.1307692307692307,3.5676923076923077,4.004615384615384,4.441538461538461,4.878461538461538,5.315384615384615,5.752307692307692,6.189230769230769,6.626153846153846,7.063076923076923,{"y":7.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,2.2376923076923076,2.6553846153846155,3.073076923076923,3.4907692307692306,3.9084615384615384,4.326153846153846,4.743846153846154,5.161538461538462,5.57923076923077,5.9969230769230775,6.414615384615385,6.832307692307692,{"y":7.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.82,2.2184615384615385,2.6169230769230767,3.0153846153846153,3.413846153846154,3.812307692307692,4.21076923076923,4.609230769230769,5.007692307692308,5.406153846153846,5.804615384615384,6.203076923076923,6.601538461538461,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >